File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Anti-CD47 antibody suppresses tumor growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma

TitleAnti-CD47 antibody suppresses tumor growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma
Authors
Issue Date2016
PublisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1
Citation
Liver International, 2016, v. 36 n. 5, p. 737–745 How to Cite?
AbstractBACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is often associated with metastasis and recurrence leading to a poor prognosis. Therefore, development of novel treatment regimens is urgently needed to improve the survival of HCC patients. In this study, we aimed to investigate the in vitro and in vivo effects of anti-CD47 antibody alone and in combination with chemotherapy in HCC. METHODS: In this study, we examined the functional effects of anti-CD47 antibody (B6H12) on cell proliferation, sphere formation, migration and invasion, chemosensitivity, macrophage-mediated phagocytosis, and tumorigenicity both in vitro and in vivo. The therapeutic efficacy of anti-CD47 antibody alone or in combination with doxorubicin was examined in patient-derived HCC xenograft. RESULTS: Blocking CD47 with anti-CD47 monoclonal antibody (B6H12) at 10mug/mL could suppress self-renewal, tumorigenicity and migration and invasion abilities of MHCC-97L and Huh-7 cells. Interestingly, anti-CD47 antibody synergized the effect of HCC cells to chemotherapeutic drugs including doxorubicin and cisplatin. Blockade of CD47 by anti-CD47 antibody induced macrophage-mediated phagocytosis. Using a patient-derived HCC xenograft mouse model, we found that anti-CD47 antibody (400mug/mouse) in combination with doxorubicin (2mg/kg) exerted maximal effects on tumor suppression, as compared with doxorubicin and anti-CD47 antibody alone. CONCLUSIONS: Anti-CD47 antibody treatment could complement chemotherapy which may be a promising therapeutic strategy for the treatment of HCC patients. This article is protected by copyright. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/220233
ISSN
2015 Impact Factor: 4.47
2015 SCImago Journal Rankings: 1.677

 

DC FieldValueLanguage
dc.contributor.authorLo, J-
dc.contributor.authorLau, YT-
dc.contributor.authorSo, TY-
dc.contributor.authorLu, P-
dc.contributor.authorChan, VSF-
dc.contributor.authorCheung, CH-
dc.contributor.authorChing, HH-
dc.contributor.authorCheng, YLB-
dc.contributor.authorMa, KF-
dc.contributor.authorNg, IOL-
dc.contributor.authorLee, KW-
dc.date.accessioned2015-10-16T06:33:17Z-
dc.date.available2015-10-16T06:33:17Z-
dc.date.issued2016-
dc.identifier.citationLiver International, 2016, v. 36 n. 5, p. 737–745-
dc.identifier.issn1478-3223-
dc.identifier.urihttp://hdl.handle.net/10722/220233-
dc.description.abstractBACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is often associated with metastasis and recurrence leading to a poor prognosis. Therefore, development of novel treatment regimens is urgently needed to improve the survival of HCC patients. In this study, we aimed to investigate the in vitro and in vivo effects of anti-CD47 antibody alone and in combination with chemotherapy in HCC. METHODS: In this study, we examined the functional effects of anti-CD47 antibody (B6H12) on cell proliferation, sphere formation, migration and invasion, chemosensitivity, macrophage-mediated phagocytosis, and tumorigenicity both in vitro and in vivo. The therapeutic efficacy of anti-CD47 antibody alone or in combination with doxorubicin was examined in patient-derived HCC xenograft. RESULTS: Blocking CD47 with anti-CD47 monoclonal antibody (B6H12) at 10mug/mL could suppress self-renewal, tumorigenicity and migration and invasion abilities of MHCC-97L and Huh-7 cells. Interestingly, anti-CD47 antibody synergized the effect of HCC cells to chemotherapeutic drugs including doxorubicin and cisplatin. Blockade of CD47 by anti-CD47 antibody induced macrophage-mediated phagocytosis. Using a patient-derived HCC xenograft mouse model, we found that anti-CD47 antibody (400mug/mouse) in combination with doxorubicin (2mg/kg) exerted maximal effects on tumor suppression, as compared with doxorubicin and anti-CD47 antibody alone. CONCLUSIONS: Anti-CD47 antibody treatment could complement chemotherapy which may be a promising therapeutic strategy for the treatment of HCC patients. This article is protected by copyright. All rights reserved.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1-
dc.relation.ispartofLiver International-
dc.rightsThis is the accepted version of the following article: Liver International, 2016, v. 36 n. 5, p. 737–745, which has been published in final form at http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12963/abstract-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleAnti-CD47 antibody suppresses tumor growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma-
dc.typeArticle-
dc.identifier.emailLo, J: jlo88@hku.hk-
dc.identifier.emailLau, YT: eytlau@hku.hk-
dc.identifier.emailSo, TY: soty@hku.hk-
dc.identifier.emailChan, VSF: sfvchan@hku.hk-
dc.identifier.emailChing, HH: hhching@hku.hk-
dc.identifier.emailNg, IOL: iolng@hku.hk-
dc.identifier.emailLee, KW: tkwlee@hkucc.hku.hk-
dc.identifier.authorityChan, VSF=rp01459-
dc.identifier.authorityNg, IOL=rp00335-
dc.identifier.authorityLee, KW=rp00447-
dc.description.naturepostprint-
dc.identifier.doi10.1111/liv.12963-
dc.identifier.hkuros255356-
dc.identifier.volume36-
dc.identifier.issue5-
dc.identifier.spage737-
dc.identifier.epage745-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats